Competing Risks in Clinical Trials
- 2 September 2024
- Vol. 84 (11) , 1025-1037
Abstract
No abstract availableKeywords
Funding Information
- British Heart Foundation
This publication has 31 references indexed in Scilit:
- Recurrent Events in Cardiovascular TrialsJACC, 2023
- Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard careThe Lancet Respiratory Medicine, 2022
- Considerations of Competing Risks Analysis in Cardio-Oncology StudiesJACC: Cardiooncology, 2022
- Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR –Preserved trialEuropean Journal of Heart Failure, 2022
- Covariate Adjustment in Cardiovascular Randomized Controlled TrialsJACC: Heart Failure, 2022
- Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?Statistics in Medicine, 2018
- Criteria for use of composite end points for competing risks—a systematic survey of the literature with recommendationsJournal of Clinical Epidemiology, 2017
- Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputationStatistics in Medicine, 2014
- Power and sample size considerations in clinical trials with competing risk endpointsPharmaceutical Statistics, 2006
- Testing treatment effects in the presence of competing risksStatistics in Medicine, 2005